Aldeyra Therapeutics Inc. (ALDX)
US FDA declines to approve Aldeyra's eye disease drug
The U.S. Food and Drug Administration has declined to approve Aldeyra Therapeutics' treatment for dry eye disease, the company said on Thursday.
Aldeyra Therapeutics Is Severely Undervalued Before PDUFA
Aldeyra's reproxalap faced an FDA setback but showed positive trial results, leading to a resubmitted NDA with a PDUFA date of April 2025. Despite a controversial deal with AbbVie, Aldeyra remains financially solid, with $100M in cash and potential milestone payments. The DED market is strong, and reproxalap's data surpasses competitors, indicating significant undervaluation of Aldeyra's stock.
Aldeyra Therapeutics: Key Inflection Point Ahead
Aldeyra Therapeutics is finally nearing commercialization, attracting renewed attention from some analyst firms. Drug giant AbbVie has a significant option agreement on Aldeyra's primary pipeline asset that will likely be triggered upon FDA approval in April. An updated analysis around Aldeyra Therapeutics follows in the paragraphs below.
Is the Options Market Predicting a Spike in Aldeyra Therapeutics (ALDX) Stock?
Investors need to pay close attention to Aldeyra Therapeutics (ALDX) stock based on the movements in the options market lately.
ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap
The FDA accepts Aldeyra's resubmitted NDA for topical ocular reproxalap to treat the signs and symptoms of dry eye disease. Stock rises.
Aldeyra: A Speculative Buy Amid Reproxalap's NDA Resubmission
Aldeyra Therapeutics offers a high-risk/high-reward investment opportunity with its Reproxalap program and promising pipeline beyond Reproxalap. Reproxalap has shown positive results in preclinical and clinical trials for the treatment of dry eye disease and allergic conjunctivitis. Aldeyra plans to resubmit Reproxalap's new drug application by Q4 2024, with potential FDA approval by Q2 2025, which could trigger potential milestone payments and revenue opportunities.
